505 related articles for article (PubMed ID: 25512159)
1. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer.
Rick FG; Schally AV
Urol Oncol; 2015 Jun; 33(6):270-4. PubMed ID: 25512159
[TBL] [Abstract][Full Text] [Related]
2. Agonists of luteinizing hormone-releasing hormone in prostate cancer.
Rick FG; Block NL; Schally AV
Expert Opin Pharmacother; 2013 Nov; 14(16):2237-47. PubMed ID: 23984804
[TBL] [Abstract][Full Text] [Related]
3. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
[TBL] [Abstract][Full Text] [Related]
4. Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?
Tolkach Y; Joniau S; Van Poppel H
BJU Int; 2013 Jun; 111(7):1021-30. PubMed ID: 23418666
[TBL] [Abstract][Full Text] [Related]
5. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
6. Degarelix: a new approach for the treatment of prostate cancer.
Persson BE; Kold Olesen T; Jensen JK
Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
[TBL] [Abstract][Full Text] [Related]
7. Utility of LHRH antagonists for advanced prostate cancer.
Moul JW
Can J Urol; 2014 Apr; 21(2 Supp 1):22-7. PubMed ID: 24775720
[TBL] [Abstract][Full Text] [Related]
8. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.
Rick FG; Block NL; Schally AV
Onco Targets Ther; 2013; 6():391-402. PubMed ID: 23620672
[TBL] [Abstract][Full Text] [Related]
9. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
Clinton TN; Woldu SL; Raj GV
Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy: past, present and future.
Schröder F; Crawford ED; Axcrona K; Payne H; Keane TE
BJU Int; 2012 Jun; 109 Suppl 6():1-12. PubMed ID: 22672120
[TBL] [Abstract][Full Text] [Related]
11. The role of LHRH antagonists in the treatment of prostate cancer.
Crawford ED; Hou AH
Oncology (Williston Park); 2009 Jun; 23(7):626-30. PubMed ID: 19626830
[TBL] [Abstract][Full Text] [Related]
12. Traditional androgen ablation approaches to advanced prostate cancer: new insights.
Rove KO; Crawford ED
Can J Urol; 2014 Apr; 21(2 Supp 1):14-21. PubMed ID: 24775719
[TBL] [Abstract][Full Text] [Related]
13. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
14. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.
Klotz L
Expert Opin Drug Metab Toxicol; 2015; 11(11):1795-802. PubMed ID: 26513436
[TBL] [Abstract][Full Text] [Related]
16. The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy.
Kluth LA; Shariat SF; Kratzik C; Tagawa S; Sonpavde G; Rieken M; Scherr DS; Pummer K
World J Urol; 2014 Jun; 32(3):669-76. PubMed ID: 23999854
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
18. Does Exist a Differential Impact of Degarelix
Sciarra A; Busetto GM; Salciccia S; Del Giudice F; Maggi M; Crocetto F; Ferro M; De Berardinis E; Scarpa RM; Porpiglia F; Carmignani L; Damiano R; Artibani W; Carrieri G
Front Endocrinol (Lausanne); 2021; 12():695170. PubMed ID: 34194398
[TBL] [Abstract][Full Text] [Related]
19. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
[TBL] [Abstract][Full Text] [Related]
20. [GnRH antagonists--a new therapy option for advanced prostate cancer].
Wolff JM
Aktuelle Urol; 2009 May; 40(3):159-63. PubMed ID: 19399720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
